Home
About Us
Company Overview
Innovation and Leadership
Products
Discovery
Company Highlights
Company History
Our People
Senior Management
Our Reach
Awards and Recognition
Australian Industry Participation Purchasing Policy
Positions Vacant
Legal Disclaimer
Our Products
Aridol
Current clinical trials
Aridol Distributors
Bronchitol
Current clinical trials
Bronchitol Product Information
Bronchitol Distributors
Respiratory Diseases
Named Patient Program (Compassionate Use)
Scientific Publications
Patents
Investors
ASX Announcements
ASX 2012
ASX 2011
ASX 2010
ASX 2009
ASX 2008
ASX 2007
ASX 2006
ASX 2005
ASX 2004
ASX 2003
News
Quarterly Reports
Annual Reports
Investor Presentations
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
Share Price
Shareholder Services
Join Our Mailing List
Contact Us
Events Calendar
Financial Summary
Analyst Coverage
Shareholders
Corporate Directory
Corporate Governance
SEC Filings
Pharmaxis ADRs
News
Media Releases
Media 2012
Media 2011
Media 2010
Media 2009
Media 2008
Media 2007
Media 2006
Media 2005
Media 2004
Media 2003
Quarterly Reports
Quarterly Reports 2012
Quarterly Reports 2011
Quarterly Reports 2010
Quarterly Reports 2009
Quarterly Reports 2008
Quarterly Reports 2007
Quarterly Reports 2006
Quarterly Reports 2005
Quarterly Reports 2004
Media Contact
News Feeds
New Product Pipeline
Clinical Trials
Scientific Publications
Investigator-Initiated Studies
Respiratory diseases
Patents
Contact Us
Health Professionals
Patients
Pharmaxis
Home
Latest News
21.05.2012 - Appendix 3B - Exercsie of Employee Options
21.05.2012 - Pharmaxis Submits US New Drug Application for Bronchitol
16.05.2012 - Ceasing to be a Substantial Shareholder - UBS (Amended)
10.05.2012 - Ceasing to be a Substantial Shareholder - UBS
02.05.2012 - Appendix 3B - Exercise of Employee Options
01.05.2012 - Appendix 3Z - Mr Denis Hanley
01.05.2012 - Pharmaxis Appoints New Chairman
27.04.2012 - Investor Presentation - Updated 27 April 2012
20.04.2012 - Pharmaxis Receives Approval to Market Bronchitol in the EU
19.04.2012 - Recording of Investor Conference Call - 19 April 2012
18.04.2012 - Quarterly Report to Shareholders March 2012
18.04.2012 - ASX Quarterly Cash Flow - March 2012
17.04.2012 - Conference Call Details - March 2012 Quarterly Report to Shareholders
17.04.2012 - Pharmaxis Completes Phase II Clinical Study with ASM8 in Asthma Patients
17.04.2012 - Notice of initial substantial holder - UBS
13.04.2012 - Ceasing to be a Substantial Shareholder - UBS
11.04.2012 - Notice of initial substantial holder - UBS
29.03.2012 - Pharmaxis Announces Agreement for European Supply of Bronchitol
16.03.2012 - European Regulatory Update on Bronchitol
14.03.2012 - Bronchitol to be Reimbursed in Australia
27.02.2012 - Appendix 3Y Mr Denis Hanley
03.02.2012 - Half Year Report - 31 December 2011
25.01.2012 - Recording of Investor Conference Call - 25 January 2012
24.01.2012 - Quarterly Report to Shareholders December 2011
24.01.2012 - ASX Quarterly Cash Flow - December 2011
23.01.2012 - Conference Call Details - December 2011 Quarterly Report to Shareholders
30.12.2011 - Appendix 3Y - Richard van den Broek
23.12.2011 - Notice of initial substantial - Acorn Capital Limited
20.12.2011 - Pharmaxis Files PBAC Minor Resubmission for Bronchitol
16.12.2011 - Appendix 3Y - Mr William Delaat
16.12.2011 - Appendix 3Y Mr Denis Hanley
16.12.2011 - Appendix 3Y - Dr John Villiger
16.12.2011 - Appendix 3B - Entitlements Offer Second Settlement
16.12.2011 - Appendix 3B - Exercise of Employee Options
13.12.2011 - Major Phase III Trial of Bronchitol in Bronchiectasis Reaches Recruitment Target
13.12.2011 - Results of Retail Entitlement Offer
29.11.2011 - Appendix 3B - Entitlements Offer First Settlement
25.11.2011 - Appendix 3Y - Richard van den Broek
24.11.2011 - Entitlement Offer - Notification of Ineligible Shareholders
24.11.2011 - Retail Offer Booklet
22.11.2011 - Annual General Meeting - Outcome of Resolutions
21.11.2011 - CEO Presentation to 2011 AGM
21.11.2011 - Chairman's Address to 2011 Annual General Meeting
18.11.2011 - Institutional Component of Entitlement Offer
16.11.2011 - Letter to Optionholders
16.11.2011 - Notice Under Section 708AA(2)(f) of the Corporations Act 2001
16.11.2011 - Pharmaxis announces pro-rata entitlement offer to raise up to approximately A$80 million
16.11.2011 - Request for Trading Halt
16.11.2011 - ASX Circular
16.11.2011 - Capital Raising Presentation
Category:
All
ASX 2009
ASX 2010
ASX 2011
ASX 2012
Home
Investor 2009
Investor 2010
Investor 2011
Investor 2012
Media 2010
Media 2011
Media 2012
News and Media
Quarterly 2009
Quarterly 2010
Quarterly 2011
Quarterly 2012
Media 2009
ASX Announcements
Investor Presentations
Quarterly Reports
Sec Filings
Annual
Page 1 of 6
1
2
3
4
5
Archived News